Relationship between pretreatment levels of serum Cyfra 21.1, CEA and PET metabolic parameters in NSCLC

Dogan I., Karyagar S., Karyagar S. S., Kahraman C., ALVER A.

ANNALS OF NUCLEAR MEDICINE, vol.28, no.9, pp.829-835, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 9
  • Publication Date: 2014
  • Doi Number: 10.1007/s12149-014-0877-y
  • Journal Name: ANNALS OF NUCLEAR MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.829-835
  • Keywords: Cyfra 21.1, CEA, FDG PET, MTV, TLG, Tumor burden, CELL LUNG-CANCER, RECURRENT COLORECTAL-CANCER, NEURON-SPECIFIC ENOLASE, VOLUME-BASED PARAMETERS, BARR-VIRUS DNA, CARCINOEMBRYONIC ANTIGEN, PROGNOSTIC-SIGNIFICANCE, NASOPHARYNGEAL CARCINOMA, F-18-FDG PET/CT, FDG PET/CT
  • Karadeniz Technical University Affiliated: Yes

Abstract

Objective No investigation has been conducted on the association between PET findings and serum Cyfra 21.1 and CEA levels in nonsmall cell lung cancers (NSCLC). The purpose of this study is to find out if the serum levels of Cyfra 21.1 and CEA are related to metabolic parameters by FDG PET in patients with NSCLC who had not received treatment.